Active Filters

  • (-) PSI Groups = 2222 Pharmacology
Search Results 1 - 20 of 35
Select Page
Biodistribution of site-specific PEGylated fibroblast growth factor-2
Lühmann, T., Gutmann, M., Moscaroli, A., Raschig, M., Béhé, M., & Meinel, L. (2020). Biodistribution of site-specific PEGylated fibroblast growth factor-2. ACS Biomaterials Science & Engineering, 6(1), 425-432. https://doi.org/10.1021/acsbiomaterials.9b01248
Cholecystokinin-2 receptor agonist <sup>177</sup>Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study
Rottenburger, C., Nicolas, G. P., McDougall, L., Kaul, F., Cachovan, M., Vija, A. H., … Wild, D. (2020). Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study. Journal of Nuclear Medicine, 61(4), 520-526. https://doi.org/10.2967/jnumed.119.233031
L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population
Terraneo, N., Jacob, F., Peitzsch, C., Dubrovska, A., Krudewig, C., Huang, Y. L., … Grünberg, J. (2020). L1 cell adhesion molecule confers radioresistance to ovarian cancer and defines a new cancer stem cell population. Cancers, 12(1), 217 (17 pp.). https://doi.org/10.3390/cancers12010217
Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins
Brandl, F., Merten, H., Zimmermann, M., Béhé, M., Zangemeister-Wittke, U., & Plückthun, A. (2019). Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. Journal of Controlled Release, 307, 379-392. https://doi.org/10.1016/j.jconrel.2019.06.030
Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients
Buitinga, M., Jansen, T., van der Kroon, I., Woliner-van der Weg, W., Boss, M., Janssen, M., … Gotthardt, M. (2019). Succinylated gelatin improves the theranostic potential of radiolabeled exendin-4 in insulinoma patients. Journal of Nuclear Medicine, 60(6), 812-816. https://doi.org/10.2967/jnumed.118.219980
L1CAM. Ein vielversprechendes Zellmembranprotein für therapeutische Interventionen
Grünberg, J., & Terraneo, N. (2019). L1CAM. Ein vielversprechendes Zellmembranprotein für therapeutische Interventionen. Leading Opinions Hämatologie & Onkologie.
High‐resolution SPECT imaging of stimuli‐responsive soft microrobots
Iacovacci, V., Blanc, A., Huang, H., Ricotti, L., Schibli, R., Menciassi, A., … Nelson, B. J. (2019). High‐resolution SPECT imaging of stimuli‐responsive soft microrobots. Small, 15(34), 1900709 (7 pp.). https://doi.org/10.1002/smll.201900709
Exendin-4 analogs in insulinoma theranostics
Jansen, T. J. P., van Lith, S. A. M., Boss, M., Brom, M., Joosten, L., Béhé, M., … Gotthardt, M. (2019). Exendin-4 analogs in insulinoma theranostics. Journal of Labelled Compounds and Radiopharmaceuticals, 62(10), 656-672. https://doi.org/10.1002/jlcr.3750
Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4
Kaeppeli, S. A. M., Schibli, R., Mindt, T. L., & Behe, M. (2019). Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4. EJNMMI Radiopharmacy and Chemistry, 4(1), 9 (11 pp.). https://doi.org/10.1186/s41181-019-0060-9
Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting
Kaeppeli, S. A. M., Jodal, A., Gotthardt, M., Schibli, R., & Behe, M. (2019). Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting. Molecular Pharmaceutics, 16(9), 3760-3769. https://doi.org/10.1021/acs.molpharmaceut.9b00271
Elucidating the structure−activity relationship of the pentaglutamic acid sequence of minigastrin with cholecystokinin receptor subtype 2
Ritler, A., Shoshan, M. S., Deupi, X., Wilhelm, P., Schibli, R., Wennemers, H., & Béhé, M. (2019). Elucidating the structure−activity relationship of the pentaglutamic acid sequence of minigastrin with cholecystokinin receptor subtype 2. Bioconjugate Chemistry, 30(3), 657-666. https://doi.org/10.1021/acs.bioconjchem.8b00849
Implementation of a new separation method to produce qualitatively improved <sup>64</sup>Cu
van der Meulen, N. P., Hasler, R., Blanc, A., Farkas, R., Benešová, M., Talip, Z., … Schibli, R. (2019). Implementation of a new separation method to produce qualitatively improved 64Cu. Journal of Labelled Compounds and Radiopharmaceuticals, 62(8), 460-470. https://doi.org/10.1002/jlcr.3730
Radiosynthesis and evaluation of an <sup>18</sup>F–labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma
Dialer, L. O., Jodal, A., Schibli, R., Ametamey, S. M., & Béhé, M. (2018). Radiosynthesis and evaluation of an 18F–labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. EJNMMI Radiopharmacy and Chemistry, 3(1), 1 (11 pp.). https://doi.org/10.1186/s41181-017-0036-6
Enhanced specific activity by multichelation of exendin-3 leads to improved image quality and <em>In Vivo </em>Beta cell imaging
Joosten, L., Brom, M., Peeters, H., Heskamp, S., Béhé, M., Boerman, O., & Gotthardt, M. (2018). Enhanced specific activity by multichelation of exendin-3 leads to improved image quality and In Vivo Beta cell imaging. Molecular Pharmaceutics, 15(2), 486-494. https://doi.org/10.1021/acs.molpharmaceut.7b00853
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma
Lindenblatt, D., Terraneo, N., Pellegrini, G., Cohrs, S., Spycher, P. R., Vukovic, D., … Grünberg, J. (2018). Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. BMC Cancer, 18, 922 (14 pp.). https://doi.org/10.1186/s12885-018-4836-1
Targeting of the cholecystokinin-2 receptor with the minigastrin analog <sup>177</sup>Lu-DOTA-PP-F11N: does the use of protease inhibitors further improve in vivo distribution?
Sauter, A. W., Mansi, R., Hassiepen, U., Muller, L., Panigada, T., Wiehr, S., … Fani, M. (2018). Targeting of the cholecystokinin-2 receptor with the minigastrin analog 177Lu-DOTA-PP-F11N: does the use of protease inhibitors further improve in vivo distribution? Journal of Nuclear Medicine, 60(3), 393-399. https://doi.org/10.2967/jnumed.118.207845
Evaluation of <sup>99m</sup>Tc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis
Schniering, J., Guo, L., Brunner, M., Schibli, R., Ye, S., Distler, O., … Maurer, B. (2018). Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis. Arthritis Research and Therapy, 20(1), 183 (13 pp.). https://doi.org/10.1186/s13075-018-1681-1
Novel peptide probes to assess the tensional state of fibronectin fibers in cancer
Arnoldini, S., Moscaroli, A., Chabria, M., Hilbert, M., Hertig, S., Schibli, R., … Vogel, V. (2017). Novel peptide probes to assess the tensional state of fibronectin fibers in cancer. Nature Communications, 8(1), 1793 (13 pp.). https://doi.org/10.1038/s41467-017-01846-0
Production and separation of <sup>43</sup>Sc for radiopharmaceutical purposes
Domnanich, K. A., Eichler, R., Müller, C., Jordi, S., Yakusheva, V., Braccini, S., … van der Meulen, N. P. (2017). Production and separation of 43Sc for radiopharmaceutical purposes. EJNMMI Radiopharmacy and Chemistry, 2, 14 (17 pp.). https://doi.org/10.1186/s41181-017-0033-9
Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates
Grob, N. M., Behe, M., von Guggenberg, E., Schibli, R., & Mindt, T. L. (2017). Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. Journal of Peptide Science, 23(1), 38-44. https://doi.org/10.1002/psc.2948